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Abstract: Schizophrenia is often called “the cancer of the brain” because of the lifelong, horrendous implications of
the disease. Though research has been conducted on schizophrenia for a century or more, it has just recently been
realized how large a role genetics may play in the development of the disease. This review will discuss why research
on schizophrenic genes has been difficult, what genes have been found, how the current treatments are being
revolutionized, and how to progress in this field. The difficulty in research is due in part to the complex genetics
behind the disease as well as possible environmental factors. The two genes to be discussed in depth, Neuregulin
1 and SNAP-25, are notable for their complexity. Neuregulin 1 has multiple types of isoforms and genetic variants
that could lead to schizophrenia and make it difficult to determine where the mutations might be. The SNAP-25
gene serves multiple purposes in various body and brain regions as an aid to release neurotransmitters, so it can
be difficult to say which part of the body affected by the gene could lead to a schizophrenia diagnosis. The future
of schizophrenia research could possibly involve glutamate because of its demonstrated abnormal correlation with
schizophrenia. Moreover, it’s important that future research focus not only on treating symptoms, but also the patient
as a whole.

Introduction
Schizophrenia affects approximately one
percent of the population around the world and
is often incredibly debilitating (Jia et al., 2010).
Schizophrenia is over-represented in homeless
populations, likely because the extreme symptoms of
the disease can cause people to lose their jobs and
homes (Fond et al., 2018). Schizophrenic populations
are largely underdiagnosed, undertreated, and often
have a multitude of physical and mental illnesses in
addition to the disease. Since schizophrenia is so
incapacitating, it makes sense that it is considered
one of the top twenty causes of disability in the world
(Leucht et al., 2013).
Schizophrenia is a complex disease that is
typically categorized into two different types: positive
or negative. The positive type of schizophrenia
is characterized by symptoms of hallucinations,
delusions, and disorganized thinking, while the
negative type is associated with a loss of cognitive
and social functions (Kay et al., 1987). With recent
medical advances, negative symptoms are typically
more difficult to address, as the positive symptoms
can be treated with antipsychotic medication
(Kirkpatrick et al., 2006). In a study that followed
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schizophrenic patients for seven years, the patients
with the least amount of negative symptoms were
most successful in recovering normal functions
(Milev et al., 2005).
There is no cure for schizophrenia, which is why
it remains a pertinent issue. There are a number of
treatment options available, and controversy remains
over what treatments are most effective. Often, the
symptoms of schizophrenia are treated instead of
the condition itself (Harvey et al., 2004). Even if
medication can be effective, most are expensive,
have debilitating side effects, and can lead to
serious effects if discontinued (Leucht et al., 2013).
Also, improving the symptoms of schizophrenia
through antipsychotic medication or other types
of medication does not always, or completely, help
an individual. Social functioning, the ability to live
independently, and employment are all challenges
that schizophrenics face beyond the symptoms of
their illness (Harvey et al., 2004).
Schizophrenic research is ongoing; however,
from the research already conducted, it seems that
schizophrenia is based on both environmental and
genetic factors, but especially genetic. The heritability
estimates of schizophrenic genes are approximately
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eighty percent, meaning heritability has been shown
to have a much greater effect than the environment
(Jia et al., 2010). Research suggests that a family
history of schizophrenia can be a significant risk
factor, but there are also many cases of specific
gene changes that are risk factors for schizophrenia
(Yunjung et al., 2011).
This paper will address the effect of genetics
on schizophrenia. The first objective will discuss
why research on schizophrenia has been difficult
due to the number of possible causal genes and the
complexity of those genes. The second and third
objectives will analyze specific genes that may be
linked to schizophrenia: the Neuregulin 1 gene and
SNAP-25 gene respectively. The fourth objective will
look at the current treatments, like antipsychotic
medication, and discuss future research needs in
genetics to improve schizophrenia treatments.
Schizophrenia research has come a long way;
however, there must be continued research in order
to better treat not just the symptoms, but the causes.

create a noticeable variation (Yunjung et al., 2011).
This genomic search also showed that there were no
common variations of loci to produce a strong enough
effect. The variety of information from this study
shows how difficult the genomics of schizophrenia
are to discern because the possible genetic risk
factors are often rare or polygenic. Empirical data
representing a spectrum of risk for specific alleles
related to schizophrenia are shown in Figure 1,
which shows that schizophrenic inheritance is based
on both rare, Mendelian-like genes and polygenes.

Objective 1: Difficulties in Research
While there has been extensive research on
schizophrenia, there have been multiple roadblocks
that have prevented progress. The biggest problem
has been the lack of knowledge about the underlying
structure and complexity of the genes affected
(Yunjung et al., 2011). The human genome was only
mapped out less than twenty years ago, and since
then, there has been much to learn about how certain
parts of genes can cause such detrimental effects.
There have been multiple types of studies to
determine possible causes of schizophrenia, one of
which is karyotyping, a detection of chromosome
abnormalities through the number and visual
appearance of chromosomes in a cell’s nucleus.
Karyotyping showed that a deletion of area 22q11.2
on a chromosome was a rare but potent risk factor
for schizophrenia. Similarly, specific copy number
variations (CNVs)—sections of the genome that are
repeated—showed this deletion as well as changes
on areas 15q13.3, 16p11.2, 1q21.1, and NRXN1 on
the chromosome (Yunjung et al., 2011). Through
a genomic search for loci that differ between
schizophrenic patients and non-schizophrenics,
evidence suggested that schizophrenia was
polygenic, meaning that genes with too small of a
phenotypic effect to be observed acted together to
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As aforementioned, the heritability of
schizophrenia is around eighty percent, which
means there is still a small portion of causality due to
environmental factors. However, these environmental
factors are notorious for being more difficult to
identify than the biological aspects because of the
wide range of possible factors, including drug abuse,
trauma during mother’s pregnancy, nutritional
factors, prenatal and postnatal development, and
any other possible trauma, physical or emotional
(Petronis, 2004). Since the environmental factors
of schizophrenia and other mental illnesses are
so elusive, the genomic side has dominated the
field of research. However, the genomic side is as
equally complex as the environmental factors; it
dominates the research side because the genetics can
be tested experimentally more easily than testing
traumas (Petronis, 2004). Despite the difficulties
in researching this complex disease, there has been
some progress made, as certain genes may play a role
in the development of the disease.
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Objective 2: The Neuregulin 1 Gene
The Neuregulin 1 gene is known as a schizophrenia
susceptibility gene and is also incredibly complex.
The neuregulin genes are a family of four genes
that play a key part in developmental processes,
neuroplasticity, and oncogenesis (a process in which
healthy cells become cancer cells). The Neuregulin
1 gene, located at chromosome 8p13, [0] has been
associated with key functions in the heart, breast, and
nervous system. (Harrison et al., 2003). The gene’s
structure consists of 1.4 megabases and has more
than twenty exons as seen in Figure 2. Neuregulin 1
has six isoforms for one gene (Harrison et al., 2003).
The differences in promoters can result in differences
in expression patterns between different isoforms.
If either exon E68 or E59 are in the gene, there will
be variants. Exon E68 causes an inclusion of EGFα
variants, while exon E59 leads to EGFβ variants,
and the β variants are much more potent than the α
equivalents (Steinthorsdottir et al., 2004).

polymorphisms can predict schizophrenia patients
at-risk of psychosis (Jagannath et al., 2018). Both of
these studies have supported that the Neuregulin 1
gene is part of the cause of schizophrenia; however,
it would be difficult to repair this gene because there
are so many exons and loci on the gene that could
be responsible for the schizophrenic symptoms.
Research suggests that most of the genetic variants
on Neuregulin 1 were either on introns, part of
synonymous exon substitution, or in a non-coding
region near the 5’ or 3’ end (Mei et al., 2008). These
differences are said to cause a change at the level
of transcription or splicing, and aid in showing the
complexity of this gene as to how it could cause
schizophrenia.
It is significant to have research on a gene that
is likely responsible for causing susceptibility to
schizophrenia. With the information of what genes
are responsible for creating the incorrect proteins,
research can continue to determine how this can be
prevented, or how treatments could overcome the
effects of the mutations.
Objective 3: The SNAP-25 Gene
Another gene that studies have found may
play a role in causing schizophrenia is the SNAP25 gene. This gene is part of a complex that allows
presynaptic vesicle trafficking, which also means
the gene helps to release neurotransmitters (Müller
et al., 2005). In a study of mutant mice without the
SNAP-25 gene revealed that this gene is essential for
synaptic transmission, but not for neurotransmitter
release without a stimulant (Corradini et al., 2009).
Along with this role, SNAP-25 also interacts with
different voltage-gated calcium channels. It interacts
with these channels through a region called synaptic
protein interaction and controls neuronal calcium
responsiveness to depolarization through inhibition
of the calcium channels (Corradini et al., 2009). The
SNAP-25 gene is also therefore a synaptic protein
that aids in synaptic vesicle fusion and moderating
calcium dynamics in response to depolarization, as
can be seen in Figure 3.
In schizophrenic patients, there have been
quantitative differences in the expression of SNAP25 in the brain and cerebrospinal fluid (Müller et al.,
2005). Decreased levels of the gene’s expression were
found in the hippocampus and frontal lobe within

The Neuregulin 1 protein has been noted for
binding to receptor tyrosine kinases called ErbB,
and it has also been noted that any irregularities
in the pathway of the gene and this receptor has
been found in schizophrenic patients (Jagannath
et al., 2018). A study was conducted in mice with
mutations in Neuregulin 1 and ErbB, and the mice
with the mutations showed “schizophrenic-like”
symptoms and were hyperactive (Mei et al., 2008).
It has also been shown that Neuregulin 1 gene
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Objective 4: Treatments and Future Research
While there is still much to be researched
regarding the genetics of schizophrenia, there are
treatments now to help address the symptoms of
the disease. Most of the treatments available for
the symptoms are antipsychotic medications or
cognitive behavioral therapy. As stated before in
the introduction, a majority of the antipsychotic
medications are too expensive (especially
considering the large number of schizophrenics who
are unemployed and homeless), have various side
effects, and can lead to detrimental effects when the
medication is discontinued (Leucht et al., 2013). The
antipsychotics typically reduce dopamine receptor
function which can help to defray some symptoms,
but also have dangerous side effects, such as diabetes
and an increase in blood lipids (Moghaddam, 2004).
More recent research has tried to find other
ways of treating schizophrenics beyond the
antipsychotics. One study revealed the role of
glutamate in schizophrenia because multiple
parts of the body (frontal cortical systems, limbic
system, basal ganglia, and thalamus) and multiple
connections (corticocortical, corticolimbic, and
corticothalamic) that are affected in people with
schizophrenia are glutamatergic (Moghaddam,
2004). In addition, there have been reports since the
mid-twentieth century about an abnormal amount of
glutamate and an abnormal amount of postmortem
glutamate receptor binding in schizophrenic patients
(Moghaddam, 2004). Gated ion channels known
as NMDA receptors and two ligands—glutamate
and glycine—are responsible for regulating the
release of glutamate, glycine, and D-serine through
presynaptic mechanisms (Moghaddam, 2004). These
NMDA receptors have been shown to possibly cause
schizophrenic symptoms if there is any small change
to the receptor, and factors that could cause these
changes can be seen in Figure 4. Also shown in the
figure are the pharmacological sites on the NMDA
receptor that could be used to treat schizophrenia,
such as glycine and D-serine binding sites, the
glycine transporter (Gly T), and the metabotropic
glutamate (mGlu) receptors (Moghaddam, 2004).
Another study showed similar discoveries about
glutamate and using the findings about glutamate
for future treatments. This study analyzed seven
different genes that were said to be linked with

schizophrenic patients versus healthy controls.
Researchers suggested that this decrease coincided
with the hyperactivity of other parts of the brain
that are typically associated with schizophrenia
(Corradini et al., 2009).
A study conducted on mice with a point mutation
called blind drunk or Bdr, which is associated with
the SNAP-25 gene, showed the influence of this gene
and the environment, specifically prenatal stress,
on schizophrenia. The study’s results showed that
sensorimotor deficits that were noted with only the
point mutation were increased in the presence of
prenatal stress (Oliver et al., 2009). The results also
showed that only when the mice had both the point
mutation and prenatal stress did social interaction
abnormalities arise within the offspring (Oliver et
al., 2009). These social interaction abnormalities are
similar to the social interaction abnormalities that
can be seen with the negative type of schizophrenia;
therefore, this study supports that environmental
prenatal stress and the point mutation can lead
to schizophrenic symptoms. This study not only
continues to show the possible effect that the SNAP25 gene has on increasing the risk of schizophrenia,
but also how the genetics and the environment
could possibly intertwine. While the heritability
of schizophrenia is high, the environment can also
contribute either individually or together with
genetic susceptibility, which raises a whole other set
of circumstances and obstacles to understanding this
disease.
Aisthesis

42

Volume 10, 2019

A Not-So Beautiful Mind: A Review of the Genetics of Schizophrenia

a small amount understood about the disease. The
genes discussed earlier, the Neuregulin 1 and SNAP25, are not the only genes to have been linked to
schizophrenia over the years. Other gene linkages
to have been reported include dysbindin (a protein
of a dystrophin-associated complex), Catechol-omethyltransferase (one of enzyme that degrades
catecholamines), the DISC1 (encoding a brain
protein), RGS4 (Regulator of G-protein Signaling
4), GRM3 (metabotropic glutamate receptor), and
the gene G72, which encodes a protein in the brain
thought to modulate NMDA glutamate receptor
function as discussed before (Kirov et al., 2006).
Research suggests that all of these genes have some
link to the development of schizophrenia. Although
there is knowledge about these genes, and where
they are, and what they are doing wrong, there is very
little knowledge about how to treat them or change
them (if ethically these treatments were approved).
However, even if there were a cure to treat
the genetic abnormalities that play a large part in
causing schizophrenia, many schizophrenic patients
may need help relearning societal expectations. In a
study of schizophrenic patients who had undergone
antipsychotic treatment, half of the sample had
never been married and ninety-five percent of the
sample had impaired social relationships (Harvey et
al., 2004). Within the same study, the quality of life
among schizophrenic patients was found to be low
even after they had received treatment. Many of the
patients said that their symptoms of schizophrenia
were not the reason for their lower quality of life,
and many cited medication side effects were the
main culprit (Harvey et al., 2004). The future of
schizophrenia research will likely involve addressing
the other issues patients face beyond their generalized
symptoms.

schizophrenia and found the common theme of
glutamatergic synapses among all of them (Harrison
et al., 2003). Figure 5 shows a hypothetical scenario
in which the seven genes have a shared effect on
the synapses, which supports the importance of
glutamate. By looking into these potential genetic
sites for intervention, there is hope for more than
just treating the symptoms, but actually being
able to treat, or possibly cure, the root cause of
schizophrenia.
There are decades, perhaps even centuries, of
research done on schizophrenia, but there is only

Conclusion
From 1955 to 2005, the percentage of Americans
disabled by mental illness increased fivefold to
almost six million Americans disabled (Whitaker,
1970). Schizophrenia is part of this mental illness
epidemic, as it affects almost one percent of the
worldwide population (Jia et al., 2010).
The difficulty in understanding schizophrenia
is largely due to its complexity. Environmental
factors have at least a small impact on causing these
symptoms, and these factors can take the form
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of prenatal chemicals to living emotional trauma
(Petronis, 2004). The larger complexity though comes
from genetic factors, but these are not just simple
Mendelian-like genes. For instance, the Neuregulin
1 gene can have variant introns, synonymous exon
substitution, or variants in non-coding regions (Mei
et al., 2008). Without having just one variant, it
can be difficult to determine which specific variant
is causing the abnormality. Another reason for the
difficulty is that genes like the SNAP-25 gene (where
it can be seen that there is a correlation between
schizophrenia and the gene) play a role in so many
vital parts of the body that it can be difficult to
understand how exactly SNAP-25 is affecting a
certain part (Corradini et al., 2009).
However, the understanding of genes has allowed
for some progress in the pharmacology of treating
symptoms of schizophrenia. The recent research in
how glutamate could play a role in the actual genetics
aspect of schizophrenia could make a difference in
one day finding a cure. Future endeavors in research
for schizophrenia will hopefully either provide a
solid cure for the root cause in an individual, or more
likely, will help to treat the individual in a holistic
way.
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